Hormonal
Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.
If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.
Semaglutide was effective in reducing major adverse cardiovascular events... Tirzepatide was effective in... reduction in hospitalization due to heart failure.
Why this rating
Based on RCTs, but fewer trials for specific CV outcomes compared to weight loss.
Source
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
Barbara McGowan et al. · Nature Medicine · 2025
DOI 10.1038/s41591-025-03978-z
More from this paper
- Tirzepatide and semaglutide are the only obesity management medications (OMMs) achieving greater than 10% total body weight loss (TBWL) at study endpoints, with tirzepatide uniquely associated with a significantly higher proportion of patients achieving ≥25% TBWL.Strong
- Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →